FBIO vs. CDXS, IRWD, SGMO, ACHV, AGEN, DOMH, SABS, CRIS, BOLT, and AMGN
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Agenus (AGEN), Dominari (DOMH), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), and Amgen (AMGN). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs. Its Competitors
Codexis (NASDAQ:CDXS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
Codexis has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
Fortress Biotech has a net margin of -24.84% compared to Codexis' net margin of -113.67%. Codexis' return on equity of -105.83% beat Fortress Biotech's return on equity.
78.5% of Codexis shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 1.9% of Codexis shares are held by insiders. Comparatively, 27.9% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Fortress Biotech had 2 more articles in the media than Codexis. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for Codexis. Codexis' average media sentiment score of 0.84 beat Fortress Biotech's score of 0.56 indicating that Codexis is being referred to more favorably in the media.
Fortress Biotech has lower revenue, but higher earnings than Codexis. Fortress Biotech is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.
Codexis presently has a consensus price target of $11.00, suggesting a potential upside of 354.55%. Fortress Biotech has a consensus price target of $16.50, suggesting a potential upside of 344.74%. Given Codexis' higher possible upside, research analysts plainly believe Codexis is more favorable than Fortress Biotech.
Summary
Codexis and Fortress Biotech tied by winning 8 of the 16 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 9/5/2025 by MarketBeat.com Staff
